Celltrion Group Announces Large-Scale Share Buyback Decisions
Celltrion Group Announces Large-Scale Share Repurchase Decisions Celltrion Group, under the leadership of Chairman Seo Jeong-jin, has made a significant announcement regarding the repurchase of shares by Celltrion and Celltrion Healthcare, with a total value of 300 billion won. This decision comes just two days after the completion of a 529.5 billion won share repurchase, […]
KOSPI and KOSDAQ Surge on Ban of Short Selling and Positive Market Sentiment
KOSPI Index Soars by 5.66% on Expectations of Fed Interest Rate Hike Pause The KOSPI index closed at 2,502.37, marking a 5.66% increase. This surge comes after the New York stock market experienced an uptick due to expectations of a pause in Fed interest rate hikes and a slowdown in US employment in October. Major […]
Celltrion Group Chairman Seo Jeong-jin Announces Merger Approval and Future Sales Expectations at 2023 Press Conference
Chairman Seo Jeong-jin of the Celltrion Group announced at a recent press conference that the merger between Celltrion and Celltrion Healthcare has been approved and will be completed this year. He also mentioned that Celltrion Healthcare’s sales for next year are projected to be around 3.5 trillion won. Additionally, after the merger, the operating profit […]
Celltrion Merger Plan Approved at Shareholders Meeting: What’s Next for the Celltrion Integrated Corporation?
Mega Merger between Celltrion and Celltrion Healthcare Gets Shareholder Approval The Plan to Merge The merger plan between Celltrion and Celltrion Healthcare has successfully passed the first hurdle as shareholders supported the merger at an extraordinary general meeting held on the 23rd. Despite the National Pension Service, the second largest shareholder in Celltrion, abstaining from […]
Celltrion’s ‘Remsima’ Continues to Lead European Market Share in Infliximab Offer
Celltrion Healthcare, led by CEO Kim Hyeong-ki, has announced its continued dominance in the European infliximab market with its product, Remsima. This comes as the company receives ongoing orders and maintains its status as the market leader. Most recently, Remsima secured a significant win in France, capturing a 59% market share, according to pharmaceutical market […]
Celltrion Healthcare Partners with CarePartners to Expand Uplyma Distribution in the US
Celltrion Healthcare Expands Distribution of Uplyma through CarePartners Specialty Pharmacies Celltrion Healthcare, a prominent specialty pharmacy chain in the US, has announced its partnership with CarePartners Pharmacy to distribute their flagship product, Uplyma. The adalimumab-containing drug will be exclusively available through CarePartners’ specialty pharmacies nationwide, starting at the end of this month. This collaboration ensures […]
Celtrion Healthcare’s Anticancer Biosimilar Products Gain Success in European Market Expansion
Celltrion Healthcare Expands Presence in Major European Countries with Anticancer Biosimilar Products The CEO of Celltrion Healthcare, Kim Hyeong-gi, disclosed that the company is experiencing significant success in the European market with their anticancer biosimilar products. These products have been consistently winning bids in major European countries and are continuously expanding their performance. Biosimilar for […]
Growth in Sales of Celltrion’s Biosimilars Accelerates with New Product Approvals and Increased Demand
Celltrion Healthcare and Celltrion, two major players in autoimmune disease treatments, have secured a supply agreement worth approximately 423.6 billion won. This contract, the largest quarterly supply deal ever, is driven by the increasing demand for antibody biosimilars in the US and Europe, as well as the recent approvals of Humira biosimilars Uplyma and Begzelma. […]
Celltrion Healthcare Wins Bid to Supply Uplyma for 20% of Italian Adalimumab Market
Celltrion Healthcare Secures Major Order in Italy for Uplyma Rapid Expansion in European Market for Biosimilar In a significant development, Celltrion Healthcare announced its successful bid to supply Uplyma in five major Italian provinces, including Umbria, Piemonte, Molise, Campagna, and Valle d’Aosta. These provinces account for approximately 20% of the adalimumab market in Italy. The […]
Celltrion Healthcare Celebrates 10th Anniversary of Biosimilar Remsima in Europe
[Medical News ยท Daily News = By Kim Jung-il, Reporter] Celltrion Healthcare’s biosimilar Remsima (infliximab) celebrates its 10th anniversary of European approval in September this year. To mark this milestone, a series of global campaigns will be initiated, starting with the European Enteric Disease Society 2023 (UEGW), including a global speaker tour and symposium, scheduled […]
